NASDAQ: GRAL

GRAIL (GRAL) Stock Analysis & Forecast

Nov 13 close

$115.89−5.46 (−4.5%)

Gekko Brief

AI summaryNov 9 close

GRAIL's week centers on the FDA Advisory Committee's favorable vote on the Galleri multi-cancer early detection test, along with Q3 2026 results showing Galleri revenue up 14% year-over-year to $37.3 million and quarterly test volume up roughly 24% to more than 56,000. On the earnings call, GRAL also addressed plans to cut Galleri prices to encourage adoption ahead of an expected U.S. regulatory decision in early 2027, with the company noting 4% overall revenue growth as higher volumes were partly offset by lower pricing. The last earnings reaction, on 4 November, was -14.6% even as EPS of -2.21 beat the -2.45 estimate.

Shares closed at $128.08, up 5.5% on the day, sitting above both the 50-day average of $117.51 and the 200-day average of $78.88, with the shorter average above the longer one. The GekkoIndex reads 60.2, placing GRAL in the Accumulation zone, up 4.3 over five days. Price sits 4.1% above Gekko Fair Value of $122.98.

Over the next 20 trading days, the next earnings date falls on 18 February 2027, outside that window. Options activity shows 1 unusual signal in the last 30 days, with call premium of $406,790 and no put premium recorded. Analyst coverage includes 6 buy and 4 hold ratings among 10 firms, with a consensus target of $132.56. No seasonality read is available.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

GRAIL price vs fair value

$128.30$115.89Nov ’25May ’26Nov ’26
Close $115.89200-day averageGekko Fair Value $128.30

GRAIL quick facts

Market cap
$5.21B
P/E ratio
—
Forward P/E
1.2
EPS, TTM
−$9.22
Revenue, TTM
$166.6M
Profit margin
-243.8%
Dividend yield
—
Beta
2.87
Volume
359,969 avg 876,268
1-year return
+39.0%
Typical daily move
±10.8%
Typical 20-day move
±14.7%
50-day average
$120.87
200-day average
$79.21
Next earnings
Feb 18 after close
Shares outstanding
44.96M
52-week range
$41.50$166.48

GRAIL swing-trade checklist

GRAIL scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive1 mixed0 headwinds

  • Trendmixed

    Averages disagree

    Close $115.89 sits between the 50-day ($120.87) and 200-day ($79.21) averages, or the averages disagree.

    See the chart
  • GekkoIndexsupportive

    62.3, Accumulation

    Reading 62.3 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuesupportive

    9.7% below

    Price is 9.7% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 30 days: 1 unusual options signal.

    See smart money
  • Earnings risksupportive

    Reports in 95 days

    Next report Feb 18, 2027, 95 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityno data

    No data

    Not enough years of history for a seasonal read.

A description of current data, not a recommendation. How this page works

GRAIL stock chart and price history

GRAIL closed at $115.89 on Nov 13, 2026, +39.0% over the past year, inside a 52-week range of $41.50 to $166.48.

Close50-day average200-day averageVolume
GRAIL share price, past year, with 50-day and 200-day moving averages and volume$50$75$100$125$150DecJan 2026FebMarAprMayJunJulAugSepOctNov115.89

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−14.4%
3 months
+70.8%
6 months
+87.5%
1 year
+39.0%
The full GRAL chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open GRAL in Gekko

Follow GRAIL through every session

Put GRAL on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track GRAL in GekkoFree for 7 days. No credit card required.

About GRAIL

GRAIL focuses on detecting cancer at an early stage through testing built around DNA methylation analysis. Its best-known offering, Galleri, is a screening test aimed at people over 50 who show no symptoms, designed to flag possible cancer before other signs appear. The company also offers a diagnostic aid meant to speed up the path to a confirmed diagnosis for patients whose doctors already suspect cancer is present.

Beyond its screening products, GRAIL supports clinical studies, pilot programs, and broader research and therapy development work for other parties. It also maintains a research-use-only methylation platform used in precision oncology, which can help gauge disease outlook, stratify patient risk, detect minimal residual disease, and monitor for recurrence or relapse. Together these offerings serve clinicians, researchers, and organizations working on cancer detection and treatment, in addition to individual patients.

GRAIL was incorporated in 2015 and operates out of Menlo Park, California, serving patients and partners both within the United States and abroad. Its shares are listed on the NASDAQ under the ticker GRAL.

Listed
NASDAQ
Sector
Health technology
Industry
Medical specialties
Website
grail.com

GRAIL GekkoIndex: the smart money zone

GRAIL’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 62.3, in the Accumulation zone, up 0.6 points over five sessions.

010062.3Accumulation

Up 0.6 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying8Too few readings yet
Accumulation (current zone)163+3.2%+5.3%+16.8%+51.6%
Neutral368+2.2%+5.6%+10.2%+20.3%
Distribution49+3.9%+10.0%+15.1%+32.9%
Selling10+14.9%+3.2%+9.8%−4.2%

Average GRAL share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the GRAL price, zone by zone.Track GRAL in Gekko

Is GRAIL stock overvalued? Gekko Fair Value

GRAIL trades 9.7% below Gekko Fair Value of $128.30, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what GRAIL shares are worth, recalculated every trading day.

$128.30

Gekko Fair Value, Nov 14, 2026

9.7% Undervalued

At the end of Aug 2026 the price was 10.3% above the estimate.

Gekko Fair ValueShare price, month end
$128$116Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open GRAL in Gekko

GRAIL insider and Congress trading

No open-market insider purchases were filed for GRAIL, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for GRAL in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every GRAL insider filing, plotted on the chart in Gekko.Open GRAL in Gekko

Congress trades last 90 days

No trades in GRAL were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for GRAL, plotted on the chart in Gekko.Open GRAL in Gekko

Buybacks

GRAIL has been buying back its own shares.

Bought back, quarter ended Dec 31, 2023
$14K
As a share of market cap
0.00%

From company filings.

Unusual options activity last 30 days

1signal, 100% of the flagged premium in calls.

Latest: Bullish flow on Nov 5, $407K in unusual premium.

Hedge funds and billionaires quarter ended Dec 31

0of the funds Gekko tracks hold GRAL.

0added0opened0trimmed1sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

GRAIL earnings: next date and track record

GRAIL reports on Feb 18, 2027, after the close (95 days away), and beat the EPS estimate in 7 of its last 8 reports.

7 of 8reports beat the EPS estimate
±15.8%average move across the report
2 of 8reports followed by a gain

Share-price move across each report

−22.6%Feb ’25−8.6%May ’25+3.9%Aug ’25−0.2%Nov ’25−50.9%Feb ’26+12.7%May ’26−12.8%Aug ’26−14.6%Nov ’26

Last earnings call, Nov 4, 2026 AI summary

What they said
GRAIL reported Q3 2026 results highlighted by an FDA Advisory Committee favorable vote for Galleri multi-cancer early detection test approval. NHS-Galleri and PATHFINDER-2 study results were published in New England Journal of Medicine and Nature Medicine. Clinical data showed Galleri added to standard of care identified 4x more cancers overall and produced a clinically meaningful reduction in Stage IV diagnoses across 140+ cancer types.
Guidance
GRAIL expects FDA final approval decision by early Q1 2027 following the positive Advisory Committee vote. Management is engaged in interactive FDA communications and anticipates regulatory approval enabling broader commercial deployment and reimbursement progress.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 4, 2026−$2.21
est −$2.45
+9.8%$37.54M
est $44.21M
−15.1%−14.6%
Aug 5, 2026−$2.56
est −$2.91
+12.0%$44.69M
est $42.39M
+5.4%−12.8%
May 5, 2026−$1.37
est −$1.96
+30.1%$40.79M
est $39.16M
+4.2%+12.7%
Feb 19, 2026−$2.44
est −$3.33
+26.7%$43.60M
est $43.58M
0.0%−50.9%
Nov 12, 2025−$2.46
est −$3.36
+26.8%$36.19M
est $34.60M
+4.6%−0.2%
Aug 12, 2025−$3.18
est −$3.14
−1.3%$35.54M
est $34.10M
+4.2%+3.9%
May 13, 2025−$3.10
est −$4.03
+23.1%$31.84M
est $35.20M
−9.6%−8.6%
Feb 20, 2025−$2.89
est −$4.97
+41.9%$38.25M
est $35.80M
+6.8%−22.6%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

GRAIL stock forecast and analyst price targets

Analysts’ average 12-month price target for GRAIL is $139.44, +20.3% from the last close, from 10 firms rating the stock in the last 90 days.

$139.44consensus 12-month target, +20.3% from the last close
Low $100High $175
Buy5
Hold5
Sell0

Each firm’s latest rating in the last 90 days: 10 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 10Piper SandlerHold, reiterated$130+12.2%
Nov 9GuggenheimBuy, reiterated$155+33.7%
Nov 6Mizuho SecuritiesHold, maintained$110−5.1%
Nov 5Canaccord GenuityBuy, maintained$150+29.4%
Nov 5Piper SandlerHold, maintained$74−36.1%
+16.8%average 20-day move after past Accumulation readings
±10.8%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

GRAIL market cap and key statistics

GRAIL’s market cap is $5.21B and revenue of $166.6M over the last twelve months.

Valuation

Market cap
$5.21B
Forward P/E
1.2
EPS, TTM
−$9.22
Gekko Fair Value
$128.30

Trading

Volume
359,969
Avg volume, 20 days
876,268
52-week high
$166.48
52-week low
$41.50
Shares outstanding
44.96M

Financials

Revenue, TTM
$166.6M
Profit margin
-243.8%
Return on equity
-17.3%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
2.87
Typical daily move
±10.8%
Typical 20-day move
±14.7%

GRAIL stock news this week

2 headlines about GRAIL from the past week, newest first, each linking to the publisher.

GRAIL peers

GRAIL’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
TMOThermo Fisher Scientific−0.2%Neutral15.0% above
ABTAbbott Laboratories+0.3%Neutral10.5% below
DHRDanaher0.0%Neutral4.7% above
ISRGIntuitive Surgical0.0%Neutral17.5% above
MDTMedtronic+0.7%Neutral14.2% below
SYKStryker−2.0%Neutral0.1% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Medical specialties

GRAIL stock FAQ

What is GRAIL’s market cap?

GRAIL’s market cap is $5.21B at the Nov 13, 2026 close of $115.89, with 44.96M shares outstanding.

What is the GRAIL stock forecast?

The consensus analyst 12-month price target for GRAIL is $139.44, +20.3% from the last close. Of the 10 firms that rated the stock in the last 90 days, 5 rate it a buy, 5 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is GRAIL stock overvalued or undervalued?

On Gekko’s estimate GRAIL is undervalued: the Nov 13, 2026 close of $115.89 is 9.7% below Gekko Fair Value of $128.30. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does GRAIL report earnings next?

GRAIL is expected to report on Feb 18, 2027, after the market closes (95 days away). Analysts expect earnings of −$2.38 per share on revenue of $45.58M. GRAIL beat the earnings estimate in 7 of its last 8 reports, moving 15.8% on average across the report.

What is GRAIL’s 52-week high and low?

GRAIL’s 52-week high is $166.48 and its 52-week low is $41.50; it closed at $115.89 on Nov 13, 2026, +39.0% over the past year.

Is GRAIL stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, smart money and earnings risk), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in GRAIL?

Gekko flagged 1 unusual options signal in GRAIL over the last 30 days, with $407K of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Nov 5, 2026 with $407K in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See GRAIL the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.